This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilkin, F. Articles by Deal, C. Search for Related Content PubMed PubMed Citation Articles by Wilkin, F. Articles by Deal, C.

Pediatric Adrenocortical Tumors: Molecular Events Leading to Insulin-Like Growth Factor II Gene Overexpression¹

Sainte-Justine Hospital Research Center, Departments of Pediatrics and Pathology (L.L.O.), Université de Montréal, Montréal, Québec, Canada H3T 1C5

Address all correspondence and requests for reprints to: Cheri Deal, Ph.D., M.D., Endocrine Service, Room 1706, Ste-Justine Hospital, 3175 Côte Ste-Catherine, Montréal, Québec, Canada H3T 1C5. E-mail: dealc{at}ere.umontreal.ca

It has been previously shown that adrenocortical tumors (ACT) in adults exhibit structural abnormalities in tumor DNA in approximately 30% of cases. These abnormalities involve chromosome 11p15 and include loss of heterozygosity, paternal isodisomy, and overexpression of the gene for insulin-like growth factor II (IGF2), correlating with DNA demethylation at this locus. It has been hypothesized that these events occur late in the tumorigenic process in adults and seem to correlate with a worse prognosis. We present 4 pediatric cases of ACT diagnosed at 2.5 yr, 10 months, 12 yr, and 2.2 yr. All 4 patients presented with virilization, and 1 patient also showed signs and symptoms of glucocorticoid excess. The youngest patient’s maternal aunt had surgical excision of a more than 15-cm ACT 18 yr previously, but the aunt is doing well at age 23 yr. They all had surgical removal of their tumors. The 2.5-yr-old child also received chemotherapy and radiotherapy because of capsular rupture and, after 3 local recurrences, died 3.3 yr after initial presentation. We investigated all 4 tumors for chromosome 11 structural abnormalities (11p15.5 to 11q23), IGF2 and H19 expression by competitive RT-PCR analysis, and IGF2 methylation patterns by Southern analysis. All 4 tumors (100%) showed a combination of structural abnormalities at the 11p15 locus with mosaic loss of heterozygosity involving 11p. All tumors also had significantly increased IGF2 messenger ribonucleic acid levels relative to normal adrenal (up to 36-fold) and significant IGF2 demethylation (mean, 87%). H19 messenger ribonucleic acid levels were undetectable in 3 of 4 tumors, explained in part by mosaic loss of the actively expressed maternal allele for this imprinted gene. By immunohistochemistry we were able to confirm increased IGF-II peptide levels within the tumor tissue in 10 pediatric patients, including the 4 patients described above. Concomitantly, we also observed nuclear accumulation of p53, suggesting somatic mutations. For the 10-month-old patient, sequencing revealed a p53 germline mutation. We therefore conclude that in pediatric ACT, structural abnormalities of tumor DNA and IGF2 overexpression as well as p53 mutations are very common and are therefore less useful for prognosis than in adults. Our findings support the theory that pediatric ACT, whose IGF2 expression and steroidogenesis evoke the phenotype of the fetal adrenal cortex, may arise because of defective apoptosis.

This article has been cited by other articles:

				M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al. Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531. [Abstract] [Full Text] [PDF]

				M. Doghman, T. Karpova, G. A. Rodrigues, M. Arhatte, J. De Moura, L. R. Cavalli, V. Virolle, P. Barbry, G. P. Zambetti, B. C. Figueiredo, et al. Increased Steroidogenic Factor-1 Dosage Triggers Adrenocortical Cell Proliferation and Cancer Mol. Endocrinol., December 1, 2007; 21(12): 2968 - 2987. [Abstract] [Full Text] [PDF]

				M. Doghman, M. Arhatte, H. Thibout, G. Rodrigues, J. De Moura, S. Grosso, A. N. West, M. Laurent, J.-C. Mas, A. Bongain, et al. Nephroblastoma Overexpressed/Cysteine-Rich Protein 61/Connective Tissue Growth Factor/Nephroblastoma Overexpressed Gene-3 (NOV/CCN3), a Selective Adrenocortical Cell Proapoptotic Factor, Is Down-Regulated in Childhood Adrenocortical Tumors J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3253 - 3260. [Abstract] [Full Text] [PDF]

				A. N. West, G. A. Neale, S. Pounds, B. C. Figueredo, C. Rodriguez Galindo, M. A. D. Pianovski, A. G. Oliveira Filho, D. Malkin, E. Lalli, R. Ribeiro, et al. Gene Expression Profiling of Childhood Adrenocortical Tumors Cancer Res., January 15, 2007; 67(2): 600 - 608. [Abstract] [Full Text] [PDF]

				E. M Pinto, A. E. C. Billerbeck, M. C. B. V. Fragoso, B. B. Mendonca, and A. C. Latronico Deletion Mapping of Chromosome 17 in Benign and Malignant Adrenocortical Tumors Associated with the Arg337His Mutation of the p53 Tumor Suppressor Protein J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2976 - 2981. [Abstract] [Full Text] [PDF]

				C A Longui, S H V Lemos-Marini, B Figueiredo, B B Mendonca, M Castro, R Liberatore Jr, C Watanabe, C L P Lancellotti, M N Rocha, M B Melo, et al. Inhibin {alpha}-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers J. Med. Genet., May 1, 2004; 41(5): 354 - 359. [Abstract] [Full Text] [PDF]

				J. Bertherat, L. Groussin, F. Sandrini, L. Matyakhina, T. Bei, S. Stergiopoulos, T. Papageorgiou, I. Bourdeau, L. S. Kirschner, C. Vincent-Dejean, et al. Molecular and Functional Analysis of PRKAR1A and its Locus (17q22-24) in Sporadic Adrenocortical Tumors: 17q Losses, Somatic Mutations, and Protein Kinase A Expression and Activity Cancer Res., September 1, 2003; 63(17): 5308 - 5319. [Abstract] [Full Text] [PDF]

				T. J. Giordano, D. G. Thomas, R. Kuick, M. Lizyness, D. E. Misek, A. L. Smith, D. Sanders, R. T. Aljundi, P. G. Gauger, N. W. Thompson, et al. Distinct Transcriptional Profiles of Adrenocortical Tumors Uncovered by DNA Microarray Analysis Am. J. Pathol., February 1, 2003; 162(2): 521 - 531. [Abstract] [Full Text] [PDF]

				Z.-H. Gao, S. Suppola, J. Liu, P. Heikkila, J. Janne, and R. Voutilainen Association of H19 Promoter Methylation with the Expression of H19 and IGF-II Genes in Adrenocortical Tumors J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1170 - 1176. [Abstract] [Full Text] [PDF]

				M. A. Godil, M. P. Atlas, R. I. Parker, C. J. Priebe, M. M. Zerah, P. Kane, J. Tsung, and T. A. Wilson Metastatic Congenital Adrenocortical Carcinoma: A Case Report with Tumor Remission at 31/2 Years J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 3964 - 3967. [Abstract] [Full Text]